■ Ms. McMahon assured senators that she would be a vigilant opponent of restrictive government regulations. A background investigation of Mr. Price says he understated the value of his investments in an Australian pharmaceutical company, Innate Immunotherapeutics, and claimed income tax deductions that he could not substantiate. The findings emerged from a review of Mr. Price’s tax returns and other official documents by committee staff members from both parties. In a questionnaire in December, the committee staff said, Mr. Price understated the value of 400, 613 shares of the Australian company that he purchased in August 2016 through "a private placement offering. 